A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults

Background: Antiretroviral therapy (ART) is the cornerstone for the treatment of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). Our study aimed to compare the impact of early versus delayed access to ART over clinical and immunological outcomes in HIV-positive adults....

Full description

Bibliographic Details
Main Authors: Vikas Kumar, Ankita Sharma, Jatinder Singh, Harpreet Singh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Journal of Family Medicine and Primary Care
Subjects:
Online Access:http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=11;spage=6959;epage=6969;aulast=Kumar
_version_ 1797954840159059968
author Vikas Kumar
Ankita Sharma
Jatinder Singh
Harpreet Singh
author_facet Vikas Kumar
Ankita Sharma
Jatinder Singh
Harpreet Singh
author_sort Vikas Kumar
collection DOAJ
description Background: Antiretroviral therapy (ART) is the cornerstone for the treatment of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). Our study aimed to compare the impact of early versus delayed access to ART over clinical and immunological outcomes in HIV-positive adults. Methods: The prospective, randomized, open-label study was conducted for nine months, and comprised HIV-positive adults who presented to the ART center. Patients who presented early in their course of disease with baseline cluster of differentiation (CD) 4 count ≥350/mm3 were recruited in the early arm and in the late arm, if <350/mm3. The primary objectives were to evaluate disease progression in terms of the Centers for Disease Control and Prevention (CDC) stages, functional status, and opportunistic infections. Statistical analysis was done by applying an unpaired t-test, analysis of variance (ANOVA), Chi-square test, and Kaplan–Meier analysis with a P value <0.05 as significant at a 95% confidence interval. Results: A total of 134 HIV-positive patients meeting eligibility criteria were randomized. All patients including 60 in the early and 74 in the late arm received tenofovir + lamivudine + efavirenz (TLE). There was a significant difference in CDC stages and immunological status at baseline and post ART initiation (p-value < 0.001). TB-HIV co-infections were significantly (p-value = 0.006) more in late arm. Conclusion: The study suggests CD4 counts at ART initiation, as the most important factor in predicting post-treatment recovery in terms of clinical and immunological outcomes.
first_indexed 2024-04-10T23:24:54Z
format Article
id doaj.art-1834cadba3534fed885729ef3cb9462c
institution Directory Open Access Journal
issn 2249-4863
language English
last_indexed 2024-04-10T23:24:54Z
publishDate 2022-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Family Medicine and Primary Care
spelling doaj.art-1834cadba3534fed885729ef3cb9462c2023-01-12T12:42:32ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632022-01-0111116959696910.4103/jfmpc.jfmpc_493_22A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adultsVikas KumarAnkita SharmaJatinder SinghHarpreet SinghBackground: Antiretroviral therapy (ART) is the cornerstone for the treatment of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). Our study aimed to compare the impact of early versus delayed access to ART over clinical and immunological outcomes in HIV-positive adults. Methods: The prospective, randomized, open-label study was conducted for nine months, and comprised HIV-positive adults who presented to the ART center. Patients who presented early in their course of disease with baseline cluster of differentiation (CD) 4 count ≥350/mm3 were recruited in the early arm and in the late arm, if <350/mm3. The primary objectives were to evaluate disease progression in terms of the Centers for Disease Control and Prevention (CDC) stages, functional status, and opportunistic infections. Statistical analysis was done by applying an unpaired t-test, analysis of variance (ANOVA), Chi-square test, and Kaplan–Meier analysis with a P value <0.05 as significant at a 95% confidence interval. Results: A total of 134 HIV-positive patients meeting eligibility criteria were randomized. All patients including 60 in the early and 74 in the late arm received tenofovir + lamivudine + efavirenz (TLE). There was a significant difference in CDC stages and immunological status at baseline and post ART initiation (p-value < 0.001). TB-HIV co-infections were significantly (p-value = 0.006) more in late arm. Conclusion: The study suggests CD4 counts at ART initiation, as the most important factor in predicting post-treatment recovery in terms of clinical and immunological outcomes.http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=11;spage=6959;epage=6969;aulast=Kumaraidsantiretroviral therapycd4 countshiv
spellingShingle Vikas Kumar
Ankita Sharma
Jatinder Singh
Harpreet Singh
A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
Journal of Family Medicine and Primary Care
aids
antiretroviral therapy
cd4 counts
hiv
title A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
title_full A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
title_fullStr A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
title_full_unstemmed A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
title_short A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults
title_sort randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in hiv positive adults
topic aids
antiretroviral therapy
cd4 counts
hiv
url http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=11;spage=6959;epage=6969;aulast=Kumar
work_keys_str_mv AT vikaskumar arandomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT ankitasharma arandomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT jatindersingh arandomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT harpreetsingh arandomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT vikaskumar randomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT ankitasharma randomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT jatindersingh randomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults
AT harpreetsingh randomizedprospectivestudytocompareearlyversusdelayedaccesstoantiretroviraltherapyoverclinicalandimmunologicalsequelinhivpositiveadults